Mitral Valve Disease (MMVD) in Dogs: Stages, Signs, and Evidence-Based Treatment

Myxomatous mitral valve disease — usually abbreviated MMVD and also called degenerative or chronic valvular heart disease — is the single most common heart disease in dogs. According to the 2019 ACVIM Consensus Guidelines, MMVD accounts for roughly 75% of all canine cardiovascular disease, and its prevalence rises steeply with age and small body size. The good news: most affected dogs spend years feeling completely well, and modern medicine — particularly the drug pimobendan, validated in the landmark EPIC trial — can delay heart failure by more than a year on average. This guide explains what MMVD is, the breeds most at risk, the staging system every cardiologist uses, the warning signs of heart failure, and the evidence-based treatments that genuinely extend life.

What MMVD Actually Is

The mitral valve is the one-way door between the left atrium and the left ventricle of the heart. With each heartbeat, it opens to let blood in and snaps shut to keep blood from leaking backward when the ventricle contracts. In MMVD, the connective tissue inside the valve leaflets gradually accumulates a gel-like material (myxomatous degeneration), so the leaflets thicken, distort, and stop sealing properly. Over months and years, a small amount of blood leaks backward into the left atrium with every beat — this is called mitral regurgitation — and the heart has to work harder to push the same volume of blood forward. To compensate, the left atrium and left ventricle enlarge.

For most dogs, this remodeling is silent for a long time. The first clue is almost always a heart murmur picked up on a routine wellness exam: a soft, swishing sound on the left side of the chest that grows louder as the disease progresses. Eventually, in some dogs, the left atrium becomes so large that pressure backs up into the lungs, fluid leaks into the lung tissue, and congestive heart failure (CHF) develops. According to the ACVIM, roughly 30% of dogs with MMVD will progress to clinical heart failure over their lifetime; the other 70% live out their lives without ever needing emergency treatment.

The Breeds at Highest Risk

MMVD is overwhelmingly a disease of small and medium-sized breeds. Cornell University's College of Veterinary Medicine and the ACVIM cite consistent over-representation in:

• Cavalier King Charles Spaniels — by far the most affected breed. More than 50% are affected by age 5–7, and studies in older Cavaliers (≥ 8 years) have found the prevalence approaches 100%.
• Dachshunds, Chihuahuas, Miniature and Toy Poodles, Yorkshire Terriers, Maltese, Shih Tzus, Pomeranians, Bichon Frise, Cocker Spaniels, and Miniature Schnauzers.
• Large breeds are far less commonly affected, with the notable exception of some German Shepherds.

The overall lifetime risk of MMVD in small-breed dogs is roughly 10% across the whole population, but it climbs dramatically with age. By 13 years of age, an estimated 75–85% of small-breed dogs have at least mild MMVD. In Cavalier King Charles Spaniels, the genetic predisposition is so strong that responsible breed clubs and the Mitral Valve Disease Breeding Scheme recommend cardiac and echocardiographic screening of breeding dogs annually.

The ACVIM Staging System: A, B1, B2, C, D

The 2019 ACVIM Consensus Guidelines stage MMVD based on disease severity, because treatment recommendations differ dramatically by stage:

• Stage A. At-risk breed (e.g., a young Cavalier), but no murmur and no structural heart disease yet. No treatment needed; just yearly auscultation.
• Stage B1. A murmur is present and MMVD is confirmed, but the heart has not enlarged to a clinically meaningful degree on chest X-rays or echocardiogram. No medication is recommended; monitor every 6 to 12 months.
• Stage B2. A murmur is present and the left atrium and left ventricle have enlarged enough to meet specific echocardiographic and radiographic thresholds (LA:Ao ≥ 1.6, LVIDDN ≥ 1.7, and VHS > 10.5). The dog still feels well, but the heart is now under measurable strain. This is the stage at which pimobendan should be started based on the EPIC trial.
• Stage C. Current or past clinical signs of congestive heart failure caused by MMVD. The dog requires multi-drug therapy.
• Stage D. End-stage, refractory heart failure that no longer responds to standard doses. Care is intensified at home and in specialty hospitals.

The difference between B1 and B2 is the single most important treatment decision in canine cardiology — it is the difference between watchful waiting and starting a daily medication that can buy a dog more than a year of additional symptom-free life.

Warning Signs of Heart Failure (Stage C)

Owners almost never notice the disease before a murmur is found at a checkup. What owners do notice is the transition from B2 to C, when fluid begins to build up in the lungs. According to the American College of Veterinary Internal Medicine and Cornell, the most common signs are:

• A persistent, soft, "wet" or hacking cough, especially at night or after lying down — but not every coughing small-breed dog has heart failure, and many have airway collapse instead.
• Increased respiratory rate at rest. A healthy dog sleeping or resting quietly should breathe fewer than 30 breaths per minute. A consistently higher resting rate (often 40+) is one of the earliest and most reliable home indicators of developing CHF.
• Increased effort breathing — using the belly muscles to breathe, flared nostrils, or open-mouth breathing at rest.
• Exercise intolerance: tiring after a few minutes, slowing down on walks, refusing stairs.
• Episodes of fainting or collapse, especially with excitement or coughing.
• Decreased appetite, weight loss, or a distended belly (less common, suggesting right-sided failure).

A useful daily habit for owners of dogs with diagnosed MMVD is to count the sleeping respiratory rate once or twice a week and record it. A sustained increase of 20% or more above a dog's individual baseline often precedes clinical heart failure by hours to days and is a sign to call the vet immediately.

How Vets Diagnose and Stage MMVD

The workup starts with a stethoscope. The hallmark of MMVD is a left-apical systolic murmur that grows louder as the disease progresses; veterinarians grade it on a I–VI scale. Once a murmur is heard in an at-risk dog, the ACVIM-recommended workup typically includes:

• Chest radiographs (X-rays) — to measure the vertebral heart score (VHS) and look for pulmonary edema or an enlarged left atrium.
• Echocardiogram — the gold standard for staging. It measures the size of the left atrium relative to the aorta (LA:Ao) and the normalized left ventricular internal diameter (LVIDDN) — the exact numbers that distinguish stage B1 from B2.
• Blood pressure measurement.
• NT-proBNP blood test — a cardiac biomarker that can support a diagnosis of heart disease and help distinguish cardiac from non-cardiac causes of coughing or breathing changes.
• Baseline kidney values and electrolytes, because the medications used in heart failure can affect both.

Evidence-Based Treatment by Stage

For dogs in stage B1, the ACVIM does not recommend medication. The current evidence does not show that starting drugs before significant enlargement extends life or delays heart failure.

For dogs in stage B2, the recommendation changed in 2016 with the publication of the EPIC trial. EPIC was a large, international, blinded, placebo-controlled study of pimobendan in dogs with MMVD and enlarged hearts. The result was dramatic: dogs given pimobendan had a median time to onset of heart failure or cardiac death of about 1,228 days versus 766 days for placebo — roughly 15 additional months of asymptomatic life on average. Pimobendan (typically 0.25–0.3 mg/kg by mouth every 12 hours, given an hour before food) is now the standard of care for stage B2.

For dogs in stage C (clinical heart failure), the ACVIM recommends "quadruple therapy":

1. Pimobendan (a calcium sensitizer and vasodilator that improves contractility),
2. Furosemide (a loop diuretic that clears fluid from the lungs), or torsemide as an alternative,
3. An ACE inhibitor such as enalapril or benazepril, and
4. Spironolactone (an aldosterone antagonist with mild diuretic and cardiac-remodeling effects).

For dogs in stage D, refractory heart failure, treatment is intensified: higher diuretic doses, the addition of torsemide, occasional hospitalization for IV diuretics and oxygen, careful sodium restriction, and close at-home monitoring of breathing rate, weight, and appetite. In a small number of specialty centers, open-heart surgical mitral valve repair is now available and offers the prospect of a cure for selected dogs, although it is expensive and not yet widely accessible.

Day-to-Day Life and Prognosis

Dogs in stages A, B1, and even B2 typically lead normal, happy, active lives. Owners' job is mainly to keep them at a lean body weight, avoid excessive heat and overexertion, give medication on schedule, and track resting respiratory rate. Once a dog is in stage C, the median survival time on quadruple therapy is roughly 9 to 18 months, although individual outcomes vary widely and some dogs do well for two years or more. Quality of life — comfortable breathing, normal appetite, engaged behavior — is the right measure of success.

There is no convincing evidence that supplements (taurine, CoQ10, fish oil) prevent or cure MMVD in genetically predisposed dogs, though your cardiologist may recommend specific nutraceuticals in certain stages. Sodium restriction becomes meaningful in stage C; in earlier stages it is generally not necessary. And critically: never stop heart medications abruptly, even if your dog seems to be doing wonderfully on them. The medication is working precisely because the dog is on it.

The Bottom Line

Mitral valve disease is the most common heart disease in dogs, the most common cause of heart failure in small breeds, and the most rewarding canine heart condition to treat because the evidence for what works is unusually strong. The most important habits for owners are simple: keep up with annual physicals (so a murmur is caught early), follow through on the chest X-ray or echocardiogram your vet recommends after a murmur is found, start pimobendan at stage B2, and learn to count sleeping breath rates at home. Most dogs with MMVD live long, comfortable lives — and modern cardiology, more than almost any other field of small-animal medicine, has the data to back that up.